摘要:
The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
摘要:
The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
摘要:
The invention relates to methods for determining tumor status by determining antibodies specific to NY-ESO-1 in patient samples. One can determine whether a cancerous condition is progressing, regressing, or remaining stable by determining antibodies against NY-ESO-1 in a patient sample, and comparing the value obtained to a prior value. When the tumor in question expresses NY-ESO-1, a change in this value is indicative of a change in status of the cancerous condition.
摘要:
The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.
摘要:
A method for screening substances for oncogenic activity is disclosed. The method involves administering the substance to an animal lacking responsiveness to interferon.gamma. and detecting a higher frequency or earlier time of tumor formation in the test animal compared to control animals. In addition, a method is provided for predicting the aggressiveness of a tumor in a patient.
摘要:
The invention relates to the production of ganglioside specific antibodies. These antibodies are produced following immunization with lipopolysaccharide antigen of Campylobacter jejuni. The antibodies bind to monosialogangliosides, including GM2 and GM1.
摘要:
The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
摘要:
This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the colorectal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.
摘要:
The invention involves monoclonal antibodies which specifically bind to a cell surface antigen characteristic of tumor vascular endothelium. The antigen, referred to as endosialin, is a glycoprotein and has a molecular weight of about 165 kDa as determined by SDS-PAGE. The protein portion of the molecule has a molecular weight of about 95 kDa. Also disclosed are various uses of the monoclonal antibody and the antigen.
摘要:
Monoclonal antibodies to specific cell surface antigens of human choriocarcinoma, teratocarcinoma, and normal trophoblasts are disclosed. Additionally, panels of monoclonal antibodies which may be used in phenotyping cell and tissue samples are disclosed as well.